NCT01391611View on ClinicalTrials.gov

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

PHASE2TerminatedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions

Gastrointestinal Stromal Tumor (GIST)

Interventions

DRUG

Pazopanib

800 mg; PO

Trial Locations (2)

94305

Stanford University School of Medicine, Stanford

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Kristen Ganjoo

OTHER

NCT01391611 - Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | Biotech Hunter | Biotech Hunter